Want to see ABVX full AI Analyst Report?
ABVX Stock Chart & Stats
$125.70
$2.30(1.83%)
At close: 4:00 PM EDT
$125.70
$2.30(1.83%)
Day’s Range― - ―
52-Week Range$65.67 - $148.83
Previous Close$127
Volume662.35K
Average Volume (3M)1.95M
Market Cap
$11.23B
Enterprise Value$8.27K
Total Cash (Recent Filing)$530.16M
Total Debt (Recent Filing)$45.89M
Price to Earnings (P/E)―
Beta2.80
Next Earnings
Sep 21, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.69
Shares Outstanding87,253,800
10 Day Avg. Volume1,011,403
30 Day Avg. Volume1,951,759
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)17.54
Price to Sales (P/S)0.00
P/FCF Ratio-51.21
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$161.58Price Target Upside28.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.82
Revenue Forecast (FY)$4.35M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Balance SheetAbivax’s 2025 balance sheet shows materially reduced leverage versus prior years, with very low debt relative to equity. This durability lowers refinancing and default risk, preserves flexibility to fund late-stage development or initial commercialization, and supports multi-quarter R&D programs.
Positive Phase 3 Maintenance EfficacyRobust maintenance results in a refractory UC cohort broaden efficacy evidence and demonstrate durable clinical benefit. Strong maintenance and recapture data reduce the binary regulatory/commercial risk for obefazimod, strengthening the asset’s long-term label and market positioning if NDA approval follows.
Major Near-term Equity Raise Boosting FundingA planned ~$760M ADS offering materially improves Abivax’s capital base and provides durable runway to fund NDA submission, U.S. launch preparations and Crohn’s development. Large committed proceeds reduce short-term liquidity pressure and lower dependence on frequent dilutive financings.
Bears Say
Zero 2025 Revenue And Widening LossesThe company generated no revenue in 2025 while losses more than doubled, indicating no commercial cash generation and escalating operating deficits. Persisting negative profitability erodes equity value over time and necessitates continued reliance on external capital until product revenue materializes.
Sustained High Cash BurnConsistent ~-$155M annual cash outflow reflects deep funding needs typical of late-stage biotech. Even with improved balance sheet, prolonged development timelines or regulatory delays would require further financing and risk ongoing dilution, constraining long-term capital allocation flexibility.
High Single-asset ConcentrationAbivax’s business hinges largely on one clinical-stage asset. This concentration creates binary regulatory and commercial risk: adverse trial, safety, or approval outcomes for obefazimod would materially impair revenue prospects and leave limited diversified sources of cash generation over the medium term.
Abivax SA Sponsored ADR News
ABVX FAQ
What was Abivax SA Sponsored ADR’s price range in the past 12 months?
Abivax SA Sponsored ADR lowest stock price was $65.67 and its highest was $148.83 in the past 12 months.
What is Abivax SA Sponsored ADR’s market cap?
Abivax SA Sponsored ADR’s market cap is $11.23B.
When is Abivax SA Sponsored ADR’s upcoming earnings report date?
Abivax SA Sponsored ADR’s upcoming earnings report date is Sep 21, 2026 which is in 55 days.
How were Abivax SA Sponsored ADR’s earnings last quarter?
Abivax SA Sponsored ADR released its earnings results on May 22, 2026. The company reported -$0.703 earnings per share for the quarter, beating the consensus estimate of -$0.936 by $0.233.
Is Abivax SA Sponsored ADR overvalued?
According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued.
Does Abivax SA Sponsored ADR pay dividends?
Abivax SA Sponsored ADR does not currently pay dividends.
What is Abivax SA Sponsored ADR’s EPS estimate?
Abivax SA Sponsored ADR’s EPS estimate is -0.96.
How many shares outstanding does Abivax SA Sponsored ADR have?
Abivax SA Sponsored ADR has 87,253,800 shares outstanding.
What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?
Abivax SA Sponsored ADR reported an EPS of -$0.703 in its last earnings report, beating expectations of -$0.936. Following the earnings report the stock price went up 3.623%.
Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?
Currently, no hedge funds are holding shares in ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abivax SA Sponsored ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$161.58 (28.55% Upside)
$161.58 (28.55% Upside)
Blogger Sentiment
Bullish
ABVX Sentiment 85%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 487.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
249.60%
Trailing 12-Months
Company Description
Abivax SA Sponsored ADR
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
ABVX Stock 12 Month Forecast
Average Price Target
$161.58
▲(28.55% Upside)
Technical Analysis
Ownership Overview
―
Insiders
5.47% Mutual Funds
0.44% Other Institutional Investors
93.10% Public Companies and
Individual Investors